{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:08:40Z","timestamp":1783901320188,"version":"3.55.0"},"reference-count":22,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Olanzapine is a thienobenzodiazepine class antipsychotic that strongly antagonises the 5-HT2A serotonin receptor, but acute poisonings are reported rarely. Symptoms of an overdose include disorder of consciousness, hypersalivation, myosis, and coma. Serum concentration higher than 0.1 mg\/L is toxic, while concentration above 1 mg\/L can be fatal. Here we report key data about 61 patients admitted to the National Poison Control Centre in Belgrade, Serbia over olanzapine poisoning in 2017 and 2018. The ingested doses ranged from 35 to 1680 mg, and time from ingestion to determination from two to 24 hours. In 34 patients olanzapine serum concentrations were in the therapeutic range and in 27 in the toxic range. In five patients they were higher than fatal, but only one patient died. The most common symptoms of poisoning were depressed consciousness (fluctuating from somnolence to coma), tachycardia, hypersalivation, hypotension, myosis, and high creatine kinase. All patients but one recovered fully after nonspecific detoxification and symptomatic and supportive therapy.<\/jats:p>","DOI":"10.2478\/aiht-2022-73-3635","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T10:34:04Z","timestamp":1657103644000},"page":"126-130","source":"Crossref","is-referenced-by-count":2,"title":["Olanzapine poisoning in patients treated at the National Poison Control Centre in Belgrade, Serbia in 2017 and 2018: a brief review of serum concentrations and clinical symptoms"],"prefix":"10.2478","volume":"73","author":[{"given":"Sne\u017eana","family":"\u0110or\u0111evi\u0107","sequence":"first","affiliation":[{"name":"University of Defence, Military Medical Academy Medical Faculty, National Poison Control Centre , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nata\u0161a Perkovi\u0107","family":"Vuk\u010devi\u0107","sequence":"additional","affiliation":[{"name":"University of Defence, Military Medical Academy Medical Faculty, National Poison Control Centre , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Antunovi\u0107","sequence":"additional","affiliation":[{"name":"University of Defence, Military Medical Academy Medical Faculty, National Poison Control Centre , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Kilibarda","sequence":"additional","affiliation":[{"name":"University of Defence, Military Medical Academy Medical Faculty, National Poison Control Centre , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordana Vukovi\u0107","family":"Ercegovi\u0107","sequence":"additional","affiliation":[{"name":"University of Defence, Military Medical Academy Medical Faculty, National Poison Control Centre , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmina Jovi\u0107","family":"Sto\u0161i\u0107","sequence":"additional","affiliation":[{"name":"University of Defence, Military Medical Academy Medical Faculty, National Poison Control Centre , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slavica","family":"Vu\u010dini\u0107","sequence":"additional","affiliation":[{"name":"University of Defence, Military Medical Academy Medical Faculty, National Poison Control Centre , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2022,7,7]]},"reference":[{"key":"2026071218180974979_j_aiht-2022-73-3635_ref_001","unstructured":"Ritter J, Flower R, Henderson G, Loke YK, MacEwan D, Rang H. Rang & Dale\u2019s Pharmacology. 9th ed. Amsterdam: Elsevier Science; 2019."},{"key":"2026071218180974979_j_aiht-2022-73-3635_ref_002","doi-asserted-by":"crossref","unstructured":"Fulton B, Goa KL. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 1997;53:281\u201398. doi: 10.2165\/00003495-199753020-00007","DOI":"10.2165\/00003495-199753020-00007"},{"key":"2026071218180974979_j_aiht-2022-73-3635_ref_003","unstructured":"Moffat AC, Osselton D, Widdop B, Watts J. Clarke\u2019s Analysis of Drugs and Poisons. 4th ed. London: Pharmaceutical Press; 2011."},{"key":"2026071218180974979_j_aiht-2022-73-3635_ref_004","doi-asserted-by":"crossref","unstructured":"Robertson M, McMullin M. Olanzapine concentrations in clinical serum and postmortem blood specimens-when does therapeutic become toxic? J Forensic Sci 2000;45:418\u201321. doi: 10.1520\/JFS14697J","DOI":"10.1520\/JFS14697J"},{"key":"2026071218180974979_j_aiht-2022-73-3635_ref_005","doi-asserted-by":"crossref","unstructured":"Palenzona S, Meier PJ, Kupferschmidt H, Rauber-Luethy C. The clinical picture of olanzapine poisoning with special reference to fluctuating mental status. J Toxicol Clin Toxicol 2004;42:27\u201332. doi: 10.1081\/clt-120028741","DOI":"10.1081\/CLT-120028741"},{"key":"2026071218180974979_j_aiht-2022-73-3635_ref_006","doi-asserted-by":"crossref","unstructured":"Singh LK, Praharai SK, Sahu M. Nonfatal suicidal overdose of olanzapine in an adolescent. Curr Drug Saf 2012;7:328\u20139. doi: 10.2174\/157488612804096605","DOI":"10.2174\/157488612804096605"},{"key":"2026071218180974979_j_aiht-2022-73-3635_ref_007","doi-asserted-by":"crossref","unstructured":"Arora M, Praharai SK. Nonfatal suicidal olanzapine overdose: a case report. Clin Neuropharmacol 2006;29:190\u20131. doi: 10.1097\/01.WNF.0000228175.90959.43","DOI":"10.1097\/01.WNF.0000228175.90959.43"},{"key":"2026071218180974979_j_aiht-2022-73-3635_ref_008","doi-asserted-by":"crossref","unstructured":"McAllister RK, Tutt CD, Colvin CS. Lipid 20 % emulsion ameliorates the symptoms of olanzapine toxicity in a 4-year-old. Am J Emerg Med 2012;30(6):1012.e1\u20132. doi: 10.1016\/j.ajem.2011.03.025","DOI":"10.1016\/j.ajem.2011.03.025"},{"key":"2026071218180974979_j_aiht-2022-73-3635_ref_009","doi-asserted-by":"crossref","unstructured":"Boz Z, Hu M, Yu Y, Huang XF. N-acetylcysteine prevents olanzapine-induced oxidative stress in mHypoA-59 hypothalamic neurons. Sci Rep 2020;10:19185. doi: 10.1038\/s41598-020-75356-3","DOI":"10.1038\/s41598-020-75356-3"},{"key":"2026071218180974979_j_aiht-2022-73-3635_ref_010","doi-asserted-by":"crossref","unstructured":"Keyal N, Shrestha GS, Pradhan S, Maharjan R, Acharya PS, Marhatta MN. Olanzapine overdose presenting with acute muscle toxicity. Int J Crit Illn Ini Sci 2017;7:69\u201371. doi: 10.4103\/2229-5151.201962","DOI":"10.4103\/2229-5151.201962"},{"key":"2026071218180974979_j_aiht-2022-73-3635_ref_011","unstructured":"Nelson L, Howland MA, Lewin N, Smith S, Goldfrank L, Hoffman R. Goldfrank\u2019s Toxicologic Emergencies. 11th ed. New York: McGraw Hill Education; 2019."},{"key":"2026071218180974979_j_aiht-2022-73-3635_ref_012","doi-asserted-by":"crossref","unstructured":"Tse G, Warner M, Waring S. Prolonged toxicity after massive olanzapine overdose: two cases with confirmatory laboratory data. J Toxicol Sci 2008;33:363\u20135. doi: 10.2131\/jts.33.363","DOI":"10.2131\/jts.33.363"},{"key":"2026071218180974979_j_aiht-2022-73-3635_ref_013","doi-asserted-by":"crossref","unstructured":"Morgan M, Hacket LP, Isbisiter GK. Olanzapine overdose: a series of analytically confirmed cases. Int Clin Psychopharmacol 2007;22:183\u20136. doi: 10.1097\/YIC.0b013e32805aedf5","DOI":"10.1097\/YIC.0b013e32805aedf5"},{"key":"2026071218180974979_j_aiht-2022-73-3635_ref_014","doi-asserted-by":"crossref","unstructured":"Johal BK, Shelly MP. Olanzapine overdose. Anaesthesia 2000;55:929. doi: 10.1046\/j.1365-2044.2000.01664-25.x","DOI":"10.1046\/j.1365-2044.2000.01664-25.x"},{"key":"2026071218180974979_j_aiht-2022-73-3635_ref_015","doi-asserted-by":"crossref","unstructured":"Persson H, Sj\u00f6berg G, Haines J, de Garbino J. Poisoning severity score. Grading of acute poisoning. J Clin Toxicol 1998;36:205\u201313. doi: 10.3109\/15563659809028940","DOI":"10.3109\/15563659809028940"},{"key":"2026071218180974979_j_aiht-2022-73-3635_ref_016","doi-asserted-by":"crossref","unstructured":"Yeniocak S, Kalkan A, Metin D, Demirel A, Sut R, Akkoc I. Successful intravenous lipid emulsion therapy: Olanzapine intoxication. Acute Med 2018;17:96\u20137. PMID: 29882560","DOI":"10.52964\/AMJA.0706"},{"key":"2026071218180974979_j_aiht-2022-73-3635_ref_017","doi-asserted-by":"crossref","unstructured":"Yurtlu B, Hanci V, G\u00fcr A, Turan I. Intravenous lipid infusion restores consciousness associated with olanzapine overdose. Anesth Analg 2012;114:914\u20135. doi: 10.1213\/ANE.0b013e318213f377","DOI":"10.1213\/ANE.0b013e318213f377"},{"key":"2026071218180974979_j_aiht-2022-73-3635_ref_018","doi-asserted-by":"crossref","unstructured":"Chue P, Singer P. A review of olanzapine-associated toxicity and fatality in overdose. J Psychiatry Neurosci 2003;28:253\u201361. PMCID: PMC165790","DOI":"10.1139\/jpn.0332"},{"key":"2026071218180974979_j_aiht-2022-73-3635_ref_019","doi-asserted-by":"crossref","unstructured":"Lennest\u00e5l R, Asplund C, Nilsson M, Lakso HA, Mj\u00f6rndal T, H\u00e4gg S. Serum levels of olanzapine in a non-fatal overdose. J Anal Toxicol 2007;31:119\u201321. doi: 10.1093\/jat\/31.2.119","DOI":"10.1093\/jat\/31.2.119"},{"key":"2026071218180974979_j_aiht-2022-73-3635_ref_020","doi-asserted-by":"crossref","unstructured":"Ballestros S, Mart\u00ednez M, Ballestros M, de la Torre C, Rodr\u00edguez-Borreg\u00e1n J. A severe case of olanzapine overdose with analytical data. Clin Toxicol (Phila) 2007;45:412\u20135. doi: 10.1080\/15563650601072183","DOI":"10.1080\/15563650601072183"},{"key":"2026071218180974979_j_aiht-2022-73-3635_ref_021","doi-asserted-by":"crossref","unstructured":"Hopkins L, Sunkersing J, Jaques A. Too many pills to swallow: A case of a mixed overdose. J Intensive Care Soc 2017;18:247\u201350. doi: 10.1177\/1751143717693860","DOI":"10.1177\/1751143717693860"},{"key":"2026071218180974979_j_aiht-2022-73-3635_ref_022","doi-asserted-by":"crossref","unstructured":"Lung D, Wu A, Gerona R. Cardiotoxicity in a citalopram and olanzapine overdose. J Emerg Med 2013;45:554\u20138. doi: 10.1016\/j.jemermed.2013.04.033","DOI":"10.1016\/j.jemermed.2013.04.033"}],"container-title":["Archives of Industrial Hygiene and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/aiht-2022-73-3635","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T23:29:35Z","timestamp":1783898975000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/aiht-2022-73-3635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,7,7]]},"published-print":{"date-parts":[[2022,7,7]]}},"alternative-id":["10.2478\/aiht-2022-73-3635"],"URL":"https:\/\/doi.org\/10.2478\/aiht-2022-73-3635","relation":{},"ISSN":["1848-6312"],"issn-type":[{"value":"1848-6312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,1]]}}}